{"id":455,"date":"2019-03-14T12:16:45","date_gmt":"2019-03-14T11:16:45","guid":{"rendered":"http:\/\/www.mammaprint.cz\/klinicke-studie-a-guideliny\/"},"modified":"2019-03-14T12:21:09","modified_gmt":"2019-03-14T11:21:09","slug":"klinicke-studie-a-guideliny","status":"publish","type":"page","link":"https:\/\/www.mammaprint.cz\/sk\/klinicke-studie-a-guideliny\/","title":{"rendered":"Klinick\u00e9 \u0161t\u00fadie a Guideliny"},"content":{"rendered":"

[et_pb_section bb_built=”1″ _builder_version=”3.19.4″ bottom_divider_style=”curve”][et_pb_row][et_pb_column type=”4_4″][et_pb_text admin_label=”DOPORU\u010cEN\u00c9 POSTUPY” _builder_version=”3.19.4″]<\/p>\n

ODPOR\u00da\u010cAN\u00c9 POSTUPY <\/b><\/strong><\/h2>\n

MammaPrint je zahrnut\u00fd v mnoh\u00fdch pokynoch ku klinickej praxi vyd\u00e1van\u00fdch svetovo uzn\u00e1van\u00fdmi organiz\u00e1ciami zaoberaj\u00facimi sa lie\u010dbou rakoviny. Klinick\u00e9 pokyny s\u00fa odpor\u00fa\u010dania zalo\u017een\u00e9 na d\u00f4kazoch a s\u00fa ur\u010den\u00e9 odborn\u00edkom v zdravotn\u00edctve, ktor\u00ed s\u00fa akt\u00edvni v starostlivosti o pacientov.<\/p>\n

Pokyny maj\u00fa na z\u00e1klade aktu\u00e1lnych a presk\u00faman\u00fdch d\u00f4kazov zlep\u0161i\u0165 kvalitu starostlivosti a slu\u017eieb. MammaPrint je napr\u00edklad jedin\u00fd test svojho druhu zahrnut\u00fd v pokynoch Americkej spolo\u010dnosti pre klinick\u00fa onkol\u00f3giu pre lie\u010dbu pacientov s negat\u00edvnymi uzlinami.<\/p>\n

MammaPrint zaradili do svojich odpor\u00fa\u010dan\u00fdch postupov NCCN a ASCO, ESMO,AJCC a St. Gallen.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” animation_style=”bounce”][et_pb_column type=”1_3″][et_pb_blurb image_max_width=”30%” content_max_width=”1100px” icon_font_size_last_edited=”on|desktop” _builder_version=”3.19.4″ header_level=”h3″ header_font=”Roboto|700|||||||” header_font_size=”26″ header_font_size_last_edited=”on|desktop” header_line_height=”1.7em” body_font_size=”16px” body_font_size_phone=”14px” body_font_size_last_edited=”on|phone” background_color=”#ffffff” border_radii=”|10px|10px|10px|10px” border_width_all=”3px” border_color_all=”#2ea3f2″ box_shadow_style=”preset1″ box_shadow_blur=”70px” box_shadow_color=”rgba(110,130,208,0.18)” text_orientation=”center” module_alignment=”left” custom_margin=”||0px|” custom_padding=”30px|10px|40px|10px” custom_padding_last_edited=”off|desktop” animation=”off” font_icon=”%%254%%” use_icon_font_size=”on” icon_font_size=”30px” icon_placement=”left”]<\/p>\n

ASCO – Breast Cancer Biomarkers Flipbook<\/p>\n

[\/et_pb_blurb][et_pb_button button_url=”http:\/\/eguideline.guidelinecentral.com\/i\/848809-biomarkers-in-early-breast-cancer” button_text=”Viac inform\u00e1ci\u00ed” button_alignment=”center” _builder_version=”3.19.4″ custom_button=”on” button_bg_color=”#2ea3f2″ button_border_width=”0″ button_border_radius=”5″ background_layout=”dark” custom_margin=”-25px|||” url_new_window=”on” \/][\/et_pb_column][et_pb_column type=”1_3″][et_pb_blurb image_max_width=”35%” content_max_width=”1100px” icon_font_size_phone=”32px” icon_font_size_last_edited=”on|desktop” _builder_version=”3.19.4″ header_level=”h3″ header_font=”Roboto|700|||||||” header_text_align=”center” header_font_size_phone=”26″ header_font_size_last_edited=”on|phone” header_line_height=”1.7em” body_text_align=”left” body_font_size=”16px” body_font_size_phone=”14px” body_font_size_last_edited=”on|phone” body_line_height=”1.5em” background_color=”#ffffff” border_radii=”|10px|10px|10px|10px” border_width_all=”3px” border_color_all=”#2ea3f2″ box_shadow_style=”preset1″ box_shadow_blur=”70px” box_shadow_color=”rgba(110,130,208,0.18)” text_orientation=”center” module_alignment=”left” custom_margin=”||0px|” custom_padding=”30px|10px|40px|10px” custom_padding_last_edited=”off|desktop” animation=”off” font_icon=”%%254%%” use_icon_font_size=”on” icon_font_size=”30px” icon_placement=”left”]<\/p>\n

ASCO \u2013 Breast Cancer Guideline<\/p>\n

[\/et_pb_blurb][et_pb_button button_url=”http:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2017.74.0472″ button_text=”Viac inform\u00e1ci\u00ed” button_alignment=”center” _builder_version=”3.19.4″ custom_button=”on” button_bg_color=”#2ea3f2″ button_border_width=”0″ button_border_radius=”5″ background_layout=”dark” custom_margin=”-25px|||” url_new_window=”on” \/][\/et_pb_column][et_pb_column type=”1_3″][et_pb_blurb image_max_width=”35%” content_max_width=”1100px” icon_font_size_phone=”32px” icon_font_size_last_edited=”on|desktop” _builder_version=”3.19.4″ header_level=”h3″ header_font=”Roboto|700|||||||” header_font_size_phone=”26″ header_font_size_last_edited=”on|phone” header_line_height=”1.7em” body_font_size=”16px” body_font_size_phone=”14px” body_font_size_last_edited=”on|phone” body_line_height=”2em” background_color=”#ffffff” border_radii=”|10px|10px|10px|10px” border_width_all=”3px” border_color_all=”#2ea3f2″ box_shadow_style=”preset1″ box_shadow_blur=”70px” box_shadow_color=”rgba(110,130,208,0.18)” text_orientation=”center” module_alignment=”left” custom_margin=”||0px|” custom_padding=”30px|10px|40px|10px” custom_padding_last_edited=”off|desktop” animation=”off” font_icon=”%%215%%” use_icon_font_size=”on” icon_font_size=”30px” icon_placement=”left”]<\/p>\n

NCCN – Guideline – let\u00e1k<\/p>\n

[\/et_pb_blurb][et_pb_button button_url=”https:\/\/www.agendia.com\/pdf\/M-USA-216-V1%20(2018OCT)%20-%20NCCN%20Guidelines%20Flyer.pdf” button_text=”PDF na stiahnutie” button_alignment=”center” _builder_version=”3.19.4″ custom_button=”on” button_bg_color=”#2ea3f2″ button_border_width=”0″ button_border_radius=”5″ background_layout=”dark” custom_margin=”-25px|||” \/][\/et_pb_column][\/et_pb_row][et_pb_row][et_pb_column type=”4_4″][et_pb_text admin_label=”KLINICK\u00c9 STUDIE ” _builder_version=”3.19.4″]<\/p>\n

KLINICK\u00c9 \u0160T\u00daDIE\u00a0 <\/b><\/strong><\/h2>\n

\u0160t\u00fadia MINDACT<\/b><\/strong><\/a><\/p>\n

MammaPrint podporuj\u00fa klinick\u00e9 d\u00f4kazy najvy\u0161\u0161ej mo\u017enej kvality (\u00farove\u0148 1A) z prelomovej nez\u00e1vislej \u0161t\u00fadie MINDACT publikovanej v New England Journal of Medicine v roku 2016.<\/p>\n

MINDACT je skratkou pre In Node-negative (or 1-3 positive lymph node) Disease may Avoid ChemoTherapy (\u0161t\u00fadiu \u010dipov v diagnostike ochoren\u00ed s negat\u00edvnymi uzlinami (alebo 1-3 pozit\u00edvnymi uzlinami), ktor\u00e9 umo\u017enia vyhn\u00fa\u0165 sa chemoterapii. Jednalo sa o f\u00e1zu III prospekt\u00edvnej, randomizovanej, klinickej \u0161t\u00fadie testovania rekurencie karcin\u00f3mu prsn\u00edka.<\/p>\n

\u0160t\u00fadia sk\u00famala klinick\u00fd pr\u00ednos MammaPrintu v porovnan\u00ed so \u0161tandardn\u00fdmi patologick\u00fdmi krit\u00e9riami ( alebo pri ich spolo\u010dnom vyu\u017eit\u00ed) vo v\u00fdbere pacientiek, ktor\u00e9 by pravdepodobne neprofitovali z pou\u017eitia adjuvantnej chemoterapie.<\/p>\n

\u00da\u010dastn\u00edci boli zaraden\u00ed do kateg\u00f3ri\u00ed s n\u00edzkym a vysok\u00fdm rizikom rekurencie dvoma sp\u00f4sobmi: po prv\u00e9 pod\u013ea anal\u00fdzy tkaniva n\u00e1doru s pou\u017eit\u00edm MammaPrint a po druh\u00e9 s pou\u017eit\u00edm Adjuvant!Online, n\u00e1stroja, ktor\u00fd vypo\u010d\u00edta riziko rekurencie karcin\u00f3mu prsn\u00edka na z\u00e1klade be\u017en\u00fdch klinicko-patologick\u00fdch faktorov.<\/p>\n

Pacienti s n\u00edzkym rizikom pod\u013ea klinick\u00e9ho genomick\u00e9ho hodnotenia nepodst\u00fapili chemoterapiu, zatia\u013e \u010do pacientom s vysok\u00fdm rizikom na z\u00e1klade oboch hodnoten\u00ed bolo odporu\u010den\u00e9 chemoterapiu podst\u00fapi\u0165. Pacienti s nejasn\u00fdm v\u00fdsledkom boli randomizovan\u00ed k pou\u017eitiu klinick\u00e9ho alebo genomick\u00e9ho (MammaPrint) hodnotenia k rozhodnutiu o pou\u017eit\u00ed chemoterapie.<\/p>\n

\u0160t\u00fadia PROMIS <\/b><\/strong><\/a><\/p>\n

V roku 2015 hodnotila \u0161t\u00fadia PROMIS2 (Prospective Study of MammaPrint in Breast Cancer Patients with an Intermediate Recurrence Scor \u2013 Prospekt\u00edvna \u0161t\u00fadia MammaPrintu pri karcin\u00f3me prsn\u00edka u pacientov so stredn\u00fdm rizikom rekurencie (840 pacientov s karcin\u00f3mom prsn\u00edka v po\u010diato\u010dnom \u0161t\u00e1diu, u ktor\u00fdch genomick\u00fd test Oncotype DX ur\u010dil \u201estredn\u00e9\u201c riziko rekurencie. Cie\u013eom bolo vyhodnoti\u0165 zmenu rozhodnutia lek\u00e1ra po zisten\u00ed v\u00fdsledku pod\u013ea testu MAmmaPrint.<\/p>\n

Pri anal\u00fdze podskupiny 368 pacientov, u ktor\u00fdch bolo p\u00f4vodn\u00e9 rozhodnutie o lie\u010dbe (n\u00e1a z\u00e1klade v\u00fdsledku testu Oncotype DX) v rozpore s v\u00fdsledkom MammaPrintu , u 76% pri\u0161lo k zmene pl\u00e1nu lie\u010dby, kedy bola chemoterapia pridan\u00e1 alebo zastaven\u00e1.<\/p>\n

Autori \u0161t\u00fadie dospeli k z\u00e1veru, \u017ee MAmmaPrint poskytuje klinicky cenn\u00e9 inform\u00e1cie o pacientoch, ktor\u00ed boli testom Oncotype DX (podpis 21 g\u00e9nov) klasifikovan\u00ed so stredn\u00fdm rizikom a \u017ee je mo\u017en\u00e9, \u017ee lek\u00e1ri si ho objednaj\u00fa ako prostriedok na pomoc pri stanoven\u00ed lie\u010dby pre t\u00fdchto pacientov.<\/p>\n

V 79% pr\u00edpadoch lek\u00e1ri uviedli, \u017ee c\u00edtia v\u00e4\u010d\u0161iu istotu, pokia\u013e je ich odpor\u00fa\u010danie lie\u010dby zalo\u017een\u00e9 na v\u00fdsledkoch testu MammaPrint.<\/p>\n

\u0160t\u00fadia STO \u2013 3 <\/b><\/strong><\/a><\/p>\n

V \u0161t\u00fadii publikovanej v roku 2017 bol MammaPrint pou\u017eit\u00fd k anal\u00fdze 652 pacientov s \u00fadajmi z dvadsa\u0165ro\u010dn\u00e9ho sledovania v prospekt\u00edvnej, randomizovanej \u0161t\u00fadii Stockholm Tamoxifen. <\/p>\n

\u0160t\u00fadia preuk\u00e1zala, \u017ee MammaPrint dok\u00e1\u017ee identifikova\u0165 podskupinu pacientov s mimoriadne n\u00edzkym rizikom rekurencie 20 rokov od stanovenia diagn\u00f3zy (n\u00edzke riziko neskor\u0161ej (20 rokov) rekurencie).<\/p>\n

U t\u00fdchto pacientov, z ktor\u00fdch v\u00e4\u010d\u0161ina podst\u00fapila iba dva roky lie\u010dby tamoxif\u00e9nom, bolo pozorovan\u00e9 97% dvadsa\u0165ro\u010dn\u00e9 \u0161pecifick\u00e9 pre\u017eitie. U pacientov n\u00edzkym rizikom neskor\u0161ej recid\u00edvy (20 rokov), ktor\u00ed po oper\u00e1cii nepodst\u00fapili \u017eiadnu lie\u010dbu (chemoterapiu ani hormon\u00e1lnu terapiu) bola pozorovan\u00e1 94% miera \u0161pecifick\u00e9ho pre\u017eitia.<\/p>\n

T\u00e1to inform\u00e1cia m\u00f4\u017ee lek\u00e1rom pom\u00f4c\u0165 rozhodn\u00fa\u0165 sa, \u010di ur\u010dit\u00fdm pacientom odporu\u010di\u0165 roz\u0161\u00edren\u00fa, \u0161tandardn\u00fa alebo obmedzen\u00fa hormon\u00e1lnu terapiu. Lek\u00e1rom i pacientom pon\u00faka viac mo\u017enost\u00ed, ako ochorenie lie\u010di\u0165.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row][et_pb_column type=”1_3″][et_pb_blurb image_max_width=”35%” content_max_width=”1100px” icon_font_size_phone=”32px” icon_font_size_last_edited=”on|desktop” _builder_version=”3.19.4″ header_level=”h3″ header_font=”Roboto|700|||||||” header_font_size_phone=”26″ header_font_size_last_edited=”on|phone” header_line_height=”1.7em” body_font_size=”16px” body_font_size_phone=”14px” body_font_size_last_edited=”on|phone” background_color=”#ffffff” border_radii=”|10px|10px|10px|10px” border_width_all=”3px” border_color_all=”#2ea3f2″ box_shadow_style=”preset1″ box_shadow_blur=”70px” box_shadow_color=”rgba(110,130,208,0.18)” text_orientation=”center” module_alignment=”left” custom_margin=”||0px|” custom_padding=”30px|10px|40px|10px” custom_padding_last_edited=”off|desktop” animation=”off” font_icon=”%%215%%” use_icon_font_size=”on” icon_font_size=”30px” icon_placement=”left”]<\/p>\n

SABC 2018 \u2013 Abstrakty odborn\u00fdch predn\u00e1\u0161ok Agendia<\/p>\n

[\/et_pb_blurb][et_pb_button button_url=”https:\/\/www.agendia.com\/pdf\/M-USA-215-V3%20(2018NOV)%20-%20SABCS%202018%20Abstract%20Summary%20interactive.pdf” button_text=”PDF na stiahnutie” button_alignment=”center” _builder_version=”3.19.4″ custom_button=”on” button_bg_color=”#2ea3f2″ button_border_width=”0″ button_border_radius=”5″ background_layout=”dark” custom_margin=”-25px|||” \/][\/et_pb_column][et_pb_column type=”1_3″][\/et_pb_column][et_pb_column type=”1_3″][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div> ODPOR\u00da\u010cAN\u00c9 POSTUPY MammaPrint je zahrnut\u00fd v mnoh\u00fdch pokynoch ku klinickej praxi vyd\u00e1van\u00fdch svetovo uzn\u00e1van\u00fdmi organiz\u00e1ciami zaoberaj\u00facimi sa lie\u010dbou rakoviny. Klinick\u00e9 pokyny s\u00fa odpor\u00fa\u010dania zalo\u017een\u00e9 na d\u00f4kazoch a s\u00fa ur\u010den\u00e9 odborn\u00edkom v zdravotn\u00edctve, ktor\u00ed s\u00fa akt\u00edvni v starostlivosti o pacientov. Pokyny maj\u00fa na z\u00e1klade aktu\u00e1lnych a presk\u00faman\u00fdch d\u00f4kazov zlep\u0161i\u0165 kvalitu starostlivosti a slu\u017eieb. MammaPrint je […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-455","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/pages\/455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/comments?post=455"}],"version-history":[{"count":3,"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/pages\/455\/revisions"}],"predecessor-version":[{"id":462,"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/pages\/455\/revisions\/462"}],"wp:attachment":[{"href":"https:\/\/www.mammaprint.cz\/sk\/wp-json\/wp\/v2\/media?parent=455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}